# WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms

Source: https://onco.cc/key-papers/paper-who-2022-myeloid-khoury-leukemia-2022/  
OnCo record `paper-who-2022-myeloid-khoury-leukemia-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The 2022 World Health Organization classification redefines myeloid cancers, including myelodysplastic neoplasms, acute myeloid leukaemia by genetic type, and the boundaries between them.

## Summary

Summary of the fifth-edition WHO classification of myeloid and histiocytic neoplasms, renaming myelodysplastic syndromes as myelodysplastic neoplasms, removing the 20 percent blast threshold for AML with defining genetic abnormalities, and reorganising AML, myeloproliferative neoplasms and secondary myeloid neoplasms around genetics.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Leukemia
- Year: 2022
- DOI: 10.1038/s41375-022-01613-1
- Authors: Khoury JD, Solary E, Abla O, et al.
- What it means: The names and definitions on a marrow report (for example MDS with biallelic TP53 inactivation, or AML myelodysplasia-related) come from this document or from the parallel International Consensus Classification.
- Caveats: Differs in places from the International Consensus Classification published the same year, which can complicate trial eligibility.

## Sources

- Leukemia 2022: https://doi.org/10.1038/s41375-022-01613-1
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35732831/

## Connected records

- cancers: [Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)](https://onco.cc/cancers/advanced-systemic-mastocytosis/), [Chronic myeloid leukaemia, accelerated and blast phase](https://onco.cc/cancers/cml-advanced-phase/), [Erdheim-Chester disease](https://onco.cc/cancers/erdheim-chester-disease/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/), [Indolent and smouldering systemic mastocytosis](https://onco.cc/cancers/indolent-systemic-mastocytosis/), [Rosai-Dorfman-Destombes disease](https://onco.cc/cancers/rosai-dorfman-disease/), [Secondary and therapy-related acute myeloid leukaemia](https://onco.cc/cancers/aml-secondary/)
- journals: [Leukemia](https://onco.cc/journals/leukemia/)

---
JSON: https://onco.cc/api/v1/entities/paper-who-2022-myeloid-khoury-leukemia-2022.json